**BREAKING ADVANCES**

1589  Highlights from Recent Cancer Literature

**REVIEWS**

1591  Shedding Light on Melanocyte Pathobiology In Vivo
      M. Raza Zaidi, Edward C. De Fabo, Frances P. Noonan, and Glenn Merlino

1596  Mechanisms of Ploidy Increase in Human Cancers: A New Role for Cell Cannibalism
      Matej Krajcovic and Michael Overholtzer

**PERSPECTIVE**

1602  Ribosome Biogenesis and Control of Cell Proliferation: p53 Is Not Alone
      Giulio Donati, Lorenzo Montanaro, and Massimo Derenzini

**PRIORITY REPORTS**

1608  PARP-1 Inhibition as a Targeted Strategy to Treat Ewing’s Sarcoma
      J. Chad Brenner, Felix Y. Feng, Suman Han, Sonam Patel, Siddharth V. Goyal, Laura M. Bou-Maroun, Meilan Liu, Robert Lonigro, John R. Prensner, Scott A. Tomlins, and Arul M. Chinnaiyan
      Précis: This study prompts immediate attention to reposition small-molecule inhibitors of the DNA damage response protein PARP-1, a new class of experimental agents currently in trials in the adult oncology clinic, for treatment of a particularly aggressive and deadly class of pediatric sarcomas.

1614  Receptor Tyrosine Kinase Genes Amplified in Glioblastoma Exhibit a Mutual Exclusivity in Variable Proportions Reflective of Individual Tumor Heterogeneity
      Suzanne E. Little, Sergey Popov, Alexa Jury, Dorine A. Bax, Lawrence Doey, Saha Al-Sarraj, Juliane M. Jurgensmeier, and Chris Jones
      Précis: A major challenge facing the development of molecular cancer therapeutics is the complex heterogeneity of tumors at the cellular level, a factor poorly modeled in preclinical systems currently used in drug development, where molecular variation in key pathways can limit a targeting principle depending on its proportional involvement in the tumor.

**CLINICAL STUDIES**

1621  Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
      Précis: Clinical translation of oncolytic virotherapy has been mainly disappointing, but this study describes a modification that may improve the ability to trigger tumor clearance by defeating immune escape.

**INTEGRATED SYSTEMS AND TECHNOLOGIES**

1632  Combinatorial Chemotherapeutic Efficacy in Non-Hodgkin Lymphoma Can Be Predicted by a Signaling Model of CD20 Pharmacodynamics
      John M. Harrold, Robert M. Straubinger, and Donald E. Mager
      Précis: This study offers a mathematical model that can predict the efficacy of combinatorial chemotherapy regimens, which include the CD20 agonist rituximab, a drug that is being used to treat an increasing number of human cancers.

**MICROENVIRONMENT AND IMMUNOLOGY**

1642  Dissection of T-cell Antigen Specificity in Human Melanoma
      Rikke Sick Andersen, Charlotte Albrek Thrue, Niels Junker, Rikke Lyngaa, Marco Donia, Eva Ellebæk, Inge Marie Svane, Ton N. Schumacher, Per thor Straten, and Sine Reker Hadrup
      Précis: By defining the antigens recognized by tumor-infiltrating lymphocytes, one might improve their efficacy and, in turn, improve adoptive cell therapy in cancer.
Oncolytic Virus and Anti–4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer

Précis: The preclinical proof-of-concept offered by this study suggests a strategy to improve the clinical efficacy of oncolytic viruses for cancer immunotherapy by combining them with an immune agonist antibody that may help overcome tumor-mediated immune suppression.

Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy
Sandra Van Lint, Cleo Goyvaerts, Sarah Maenhout, Lode Goethals, Aurélie Disy, Daphné Benteyn, Joeri Pen, Aude Bonehill, Carlo Heirman, Karine Breckpot, and Kris Thielemans

Précis: This study presents important progress in the rapid development of simpler kinds of dendritic cell vaccines, the first ever of which was approved for patient treatment in the United States last year.

Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy
Takuro Noguchi, Takuma Kato, Linan Wang, Yuka Maeda, Hiroshi Shiku, Shimon Sakaguchi, Lloyd J. Old, Hiroshi Shiku, and Hiroyoshi Nishikawa

Précis: Contrary to a widely held but incorrect belief in the field, intracellular tumor antigens can offer highly effective targets for monoclonal antibody–directed therapy, as shown by this preclinical study.

Reprogramming Tumor-Associated Dendritic Cells In Vivo Using miRNA Mimetics Triggers Protective Immunity against Ovarian Cancer

Précis: Findings suggest it may be feasible to modulate microRNA activities in leukocytes in the tumor microenvironment without need of viral vectors or difficult clinical implementations.

Vascular Normalization by Loss of Siah2 Results in Increased Chemotherapeutic Efficacy
Christina S.F. Wong, Jaclyn Sceneay, Colin M. House, Heloise M. Halse, Mira C.P. Liu, Joshy George, Titaina C.U. Potdevin Hunnam, Belinda S. Parker, Izak Haviv, Ze’ev Ronai, Carleen Cullinan, David D. Bowtell, and Andreas Möller

Précis: Findings offer preclinical proof-of-concept that targeting the Siah2 ubiquitin ligase that regulates the hypoxia response factor HIF-1α can relieve hypoxia, normalize tumor vasculature, and improve responses to chemotherapy.

Vanilloid Receptor-1 Regulates Neurogenic Inflammation in Colon and Protects Mice from Colon Cancer
Amaya G. Vinuesa, Rocío Sancho, Carmen García-Limones, Axel Behrens, Peter ten Dijke, Marco A. Calzado, and Eduardo Muñoz

Précis: This important study offers compelling genetic support for the intriguing concept that neuronally controlled processes of inflammation may underlie the root inflammatory microenvironment that drives the development and progression of colon cancer, with implications for targeting neuroinflammatory receptors that control these processes as a wholly novel strategy to prevent or treat this major disease.

Cancer Vaccination Drives Nanog-Dependent Evolution of Tumor Cells toward an Immune-Resistant and Stem-like Phenotype
Kyung Hee Noh, Young-Ho Lee, Ju-Hong Jeon, Tae Heung Kang, Chih-Ping Mao, T.-C. Wu, and Tae Woo Kim

Précis: An important stem cell transcription factor is found to drive development of tumoral immune resistance after therapeutic vaccinations, suggesting possible strategies to enhance cancer immunotherapy.

RORα Suppresses Breast Tumor Invasion by Inducing SEMA3F Expression
Gaofeng Xiong, Chi Wang, B. Mark Evers, Binhua P. Zhou, and Ren Xu

Précis: Findings point to an important role for the Th17 immune transcription factor RORα in preventing the establishment of an immune-suppressive tumor microenvironment in mammary tissue.
Hypoxia-Induced Autophagy Promotes Tumor Cell Survival and Adaptation to Antiangiogenic Treatment in Glioblastoma

Précis: This important study has immediate clinical implications because it suggests ways that autophagy inhibitors such as chloroquine might be combined with antiangiogenic therapies to limit a mechanism of resistance and thereby extend efficacy.

Tumor Cell–Derived Angiopoietin-like Protein ANGPTL2 Is a Critical Driver of Metastasis
Motyosho Endo, Masahiro Nakano, Tsuysoshi Kadomatsu, Shigetsuho Kusuhara, Hiroaki Kuroda, Shuji Mikami, Tai Hato, Jun Aoi, Haruki Horiguchi, Keishi Miyata, Haruki Odagiri, Tetsuro Masuda, Masahiko Harada, Hiroshi Horio, Tsunekazu Hishima, Hiroaki Nomori, Taakaishi Ito, Yutaka Tamamoto, Takashi Minami, Seiji Okada, Takashi Takahashi, Naoki Mochizuki, Hirota Iwase, and Yuichi Oike

Précis: Findings have implications for a broad-based antibody-mediated strategy to blunt metastasis in various human cancers where an angiogenesis-related factor is implicated in this process.
Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)
Sarah V. Holt, Armelle Logie, Barry R. Davies, Denis Alférez, Sarah Runswick, Sarah Fenton, Christine M. Chresta, Yi Gu, Jingchuan Zhang, Yi-Long Wu, Robert W. Wilkinson, Sylvie M. Guichard, and Paul D. Smith

Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectin–Positive Metastatic Human Melanoma Xenografts
Michele Moschetta, Francesca Pretto, Alexander Berndt, Kerstin Galler, Petra Richter, Andrea Bassi, Paolo Oliva, Edoardo Micotti, Giovanni Vallusia, Kathrin Schwager, Manuela Kaspar, Eveline Trachsel, Hartwig Kosmehl, Maria Rosa Bani, Dario Neri, and Raffaella Giavazzi

Retinoic Acid/Alpha-Interferon Combination Inhibits Growth and Promotes Apoptosis in Mantle Cell Lymphoma through Akt-Dependent Modulation of Critical Targets
Jessica Dal Col, Katy Mastorci, Damiana Antonia Faè, Elena Muraro, Debora Martorelli, Giorgio Inghirami, and Riccardo Dolcetti

Rapamycin Resistance Is Linked to Defective Regulation of Skp2
Hana Totary-Jain, Despina Sanoudou, Cula N. Dautriche, Hillary Schneller, Lester Zambrana, and Andrew R. Marks

A Universal Strategy for Adoptive Immunotherapy of Cancer through Use of a Novel T-cell Antigen Receptor
Katarzyna Urbanska, Eviropidis Lantitis, Mathilde Poussin, Rachel C. Lynn, Brian P. Gavin, Sander Kelderman, Jason Yu, Nathalie Scholler, and Daniel J. Powell Jr

Cancer Stem Cell Vaccination Confers Significant Antitumor Immunity
Ning Ning, Qin Pan, Fang Zheng, Seagal Teitz-Tennenbaum, Martin Egenti, Ji Yet, Mu Li, Christophe Ginestier, Max S. Wicha, Jeffrey S. Moyer, Mark E.P. Prince, Yingxin Xu, Xiao-Lian Zhang, Shiang Huang, Alfred E. Chang, and Qiao Li

Significant Antitumor Immunity
Vaccines that use purified cancer stem cells are highly immunogenic and trigger antitumor immunity with greater potency than that triggered by vaccines composed of unselected tumor cells.
miRNA Signatures Associate with Pathogenesis and Progression of Osteosarcoma
Kevin B. Jones, Zaidoun Salah, Sara Del Mare, Marco Galasso, Eugenio Gaudio, Gerard J. Nuovo, Francesca Lovat, Kimberly LeBlanc, Jeff Palatini, R. Lor Randall, Stefano Volinia, Gary S. Stein, Carlo M. Croce, Jane B. Lian, and Rami I. Aqeilan
Précis: Osteosarcoma is a leading cause of death in adolescents yet remains mainly devoid of development of sounder tools to improve prognosis or therapy.

Pten Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells
David J. Mulholland, Naoko Kobayashi, Marcus Ruscetti, Allen Zhi, Linh M. Tran, Jiaoti Huang, Martin Gleave, and Hong Wu
Précis: Development of a prostate cancer model that addresses the major metastatic burden accompanying late-stage human disease addresses a gap in the field that may permit the development of more effective targeted treatment strategies.

Jab1/CSN5 Negatively Regulates p27 and Plays a Role in the Pathogenesis of Nasopharyngeal Carcinoma
Yunbao Pan, Qingshu Zhang, Ling Tian, Xin Wang, Xiaohang Fan, Huizhong Zhang, Francois X. Claret, and Huiling Yang
Précis: Definition of a cell-cycle regulatory role for a component of the signalosome, a protein turnover complex analogous to the proteosome but less understood, suggests new strategies to treat an aggressive cancer endemic in East Asia.

Lactate-Induced IL-8 Pathway in Endothelial Cells—Letter
Céline Pinheiro, Adhemar Longatto-Filho, Rosete Nogueira, Fernando Schmitt, and Fatima Baltazar
Lactate-Induced IL-8 Pathway in Endothelial Cells—Response
Frédérique Végran, Emmanuel Seront, Pierre Sonveaux, and Olivier Feron

Correction: Significance of MAD2 Expression to Mitotic Checkpoint Control in Ovarian Cancer Cells

ABOUT THE COVER
Tumor metastasis represents a major cause of cancer mortality. Despite intense effort, strategies designed to inhibit metastasis have been unsuccessful, in part due to lack of understanding of mechanisms underlying the process. In this study, a shortened period of disease-free survival was observed after surgery in lung cancer patients showing high angiopoietin-like protein 2 (ANGPTL2) expression in tumor cells within primary tumor sites. Furthermore, tumor cell–derived ANGPTL2 increased tumor cell motility and invasive capacity in an autocrine/paracrine manner, resulting in acquisition of metastatic tumor phenotypes. In tumor cell–implanted mouse models, tumor cell–derived ANGPTL2 accelerated metastasis and shortened survival periods; conversely, decreasing ANGPTL2 expression in tumor cells significantly attenuated metastasis and extended survival periods. This image represents CD44-stained human breast tumor cells expressing ANGPTL2 in lung metastasis in mice. For details, see the article by Endo and colleagues on page 1784 of this issue.
Cancer Research

72 (7)


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/72/7

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.